Halladay Benjamin 4
4 · Esperion Therapeutics, Inc. · Filed Sep 18, 2025
Insider Transaction Report
Form 4
Halladay Benjamin
Chief Financial Officer
Transactions
- Sale
Common Stock
2025-09-17$2.81/sh−7,046$19,785→ 474,862 total
Footnotes (2)
- [F1]Shares were sold to satisfy tax obligation on vested shares of restricted stock units.
- [F2]Includes 7,446 shares recently acquired in Esperion's Employee Stock Purchase Plan.